While shown to be effective in renal-specific cells, a potent NME2 inhibitor in PCa/CRPC settings is yet to be discovered and would constitute an effective combination strategy for high-MYC and high-NME2 CRPC patients. This evidence concerns the gene NME2 and posterior cortical atrophy.